Medical Condition News

RSS

FDA grants Fast Track designation to Corthera's relaxin for treating acute heart failure

Corthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to relaxin, the company's investigational drug for the treatment of acute heart failure (AHF). The Fast Track program facilitates the development and expedites the review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

3 Oct 2009

Eye treatment reimbursement change could cost Medicare millions

A change in the reimbursement rate for the drug Avastin, used off-label to treat an eye illness in the elderly, could lead Medicare doctors to use a much costlier drug that would cost the system millions, The New York Times reports.

3 Oct 2009

Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study

Telik, Inc. today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10.

3 Oct 2009

American Kidney Fund to host national gala to support kidney care community

In celebration of people who are living with kidney disease, as well as the individuals and corporations who are working to improve the lives of kidney patients, the American Kidney Fund will host its first national gala, The Hope Affair, at the Newseum on October 6.

3 Oct 2009

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

ALL initiative three-year clinical observational study results published

A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.

3 Oct 2009

Angelman Syndrome Foundation increases grant award for 2009 for AS research

The Angelman Syndrome Foundation further solidified its dedication to research by increasing its grant award total to more than $1 million for 2009. Most recently, more than $988,000 in grants was awarded to six principle investigators, focusing on Angelman Syndrome (AS) research.

3 Oct 2009

American Airlines' initiative to fight breast cancer

In honor of National Breast Cancer Awareness Month, American Airlines is inviting consumers to join the fight against breast cancer when purchasing an American Airlines Gift Card. During October, when gift card buyers specify Komen as the beneficiary, American will donate $5 to Susan G. Komen for the Cure® for every $50 of travel purchased via the American Airlines Gift Card.

3 Oct 2009

61 institutions awarded grants for cancer research from American Cancer Society

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 new national research and training grants totaling $45,097,000 to 61 institutions nationwide in the second of two grants cycles for 2009. The grants go into effect beginning January 1, 2010.

3 Oct 2009

Array BioPharma to present poster on ARRY-403 glucokinase activator

Array BioPharma Inc. today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

2 Oct 2009

sNDA for Clonicel submitted to the FDA

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

2 Oct 2009

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

AFRESA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, according to data presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes.

2 Oct 2009

Mayo study reveals infliximab reduces the need for colectomy

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

1 Oct 2009

People with rare mutations of gene MUTYH at increased risk of bowel cancer

CANCER RESEARCH UK funded scientists have found that people who carry rare mutations within both copies of a gene called MUTYH are 28 times more likely to develop bowel cancer compared to the general population, according to a study in the Journal of Clinical Oncology.

1 Oct 2009

New software to detect multiple sclerosis before brain damage occurs

Researchers of the Unit for Systems Biology of the University of Jaén, led by Francisco J. Esteban, are developing a software for clinical use to detect multiple sclerosis even before the typical brain damage of this neurodegenerative disease appear. In order to do so, this scientific multidisciplinary team is calculating the fractal dimension of the brain images registered on magnetic resonance imaging.

1 Oct 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

Catalyst Pharmaceutical Partners, Inc. today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction.

1 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009

Women create nationwide movement to eradicate breast cancer

More than 300,000 women from across the U.S. have signed up for the Love/Avon Army of Women creating a nationwide movement to eradicate breast cancer. Eighty percent of the women who have joined the Army of Women have never had breast cancer, but want to play a role in ending the disease once and for all.

1 Oct 2009

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Women with psoriasis and psoriatic arthritis are markedly more likely than men to suffer from the emotional and psychological effects of the diseases, according to survey data released by the National Psoriasis Foundation today.

1 Oct 2009